Physician profile
John A Hartman
NPI 1225032832
$551.43
in general payments reported to CMS, 2019-2025
13 companies · $149 in 2025
The $149 reported for 2025 was less than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $121 · 2024: $281 · 2025: $149.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $551.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $551.43 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $220.40 | 2023-2025 | |
| Aimmune Therapeutics, INC. | $54.18 | 2025 | Zenpep |
| Lilly USA, LLC | $40.98 | 2024 | Mounjaro, Trulicity |
| Globus Medical, INC. | $38.19 | 2025 | Senza |
| Exact Sciences Corporation | $37.16 | 2024 | Cologuard Collection Kit |
| Phathom Pharmaceuticals, INC. | $27.00 | 2024 | Voquezna |
| Braeburn INC. | $23.42 | 2025 | Brixadi |
| Janssen Pharmaceuticals, INC | $22.29 | 2024 | Spravato |
| Axsome Therapeutics, INC. | $20.69 | 2024 | Auvelity |
| Novo Nordisk INC | $20.01 | 2023 | Ozempic, Rybelsus |
| Lundbeck LLC | $19.43 | 2024 | Rexulti |
| Glaxosmithkline, LLC. | $14.17 | 2024 | Trelegy Ellipta |
| Novartis Pharmaceuticals Corporation | $13.51 | 2023 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Hartman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.